A New Push for Cell Replacement Therapies: What's Happening in Type 1 Diabetes Research

Over the past few decades, scientists have made real progress in developing cell replacement therapies for type 1 diabetes. Research has shown that manufactured islets—the cells that produce insulin—can be safely implanted into people and function properly. This is significant proof that the basic science works.

However, creating therapies that are effective, accessible, and practical for the broader type 1 diabetes community remains a challenge. One major hurdle is that current approaches often require broad immunosuppression, meaning people would need to take medications to suppress their immune system to prevent rejection of the transplanted cells. Researchers are now focused on overcoming this barrier.

To speed up the development of cell replacement therapies, Breakthrough T1D launched Project ACT (Accelerate Cell Therapies). This initiative takes a comprehensive approach by working simultaneously on research, regulatory policies, and strategies for patient access and adoption of manufactured islet therapies.

Project ACT represents a shift toward treating cell therapy development as a coordinated global effort rather than isolated research projects. By aligning funding, expertise, and regulatory guidance in one initiative, researchers hope to move therapies from the laboratory to patients faster than traditional timelines would allow.

Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network have joined forces to fund four new projects led by Canadian researchers. The partnership issued a joint request for applications and pooled resources to identify and support high-impact research in manufactured islet therapies.

This collaboration highlights how cell therapy research is becoming increasingly global and interconnected. By bringing together organizations and researchers across borders, these partnerships can share expertise, avoid duplicating efforts, and accelerate progress on therapies that don't require broad immunosuppression.

Beyond cell therapy development, researchers worldwide are exploring multiple approaches to addressing type 1 diabetes. The INNODIA network, a global partnership of over 31 academic institutions, industry partners, and patient organizations, is conducting clinical trials to advance how scientists predict, evaluate, and prevent type 1 diabetes progression.

These complementary research efforts—from cell replacement therapies to prevention and early intervention strategies—represent the diverse ways the scientific community is working toward solutions for type 1 diabetes. Each approach builds knowledge that can inform and support the others.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 4 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.